🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

RecruitingPhase 2Ages 18 Years - anyAllUniversity Hospital, Lille
NCT05561634 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy. In these particular situations, surgery and radiotherapy are sometimes not appropriate, and Sonic Hedgehog inhibitors (SHHi) (Vismodegib and Sonidegib) can be proposed. SHHi are effective treatments in laBCC but most CR patients discontinue treatment because of tolerability. Approximately 65% of the population experience a relapse after discontinuation. A few cases of patients treated concomitantly by radiotherapy and vismodegib have been reported in the literature, suggesting that combining vismodegib and concomitant radiotherapy results in an improved overall response compared to a single modality treatment. There is no study evaluating a "consolidation radiotherapy" after complete response to SHHi. We carry out a prospective mu

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient over 18 years * Locally advanced non-recurrent BCC in complete response after first course of SHHi * Complete response has to be confirmed histologically * Available photography or CT scan before SHHi treatment allowing delineation of the initial tumor Exclusion Criteria: * Patients with distant metastasis * Patients with Gorlin's syndrome * Prior radiotherapy to the region of the studied cancer that would result in overlap of radiation therapy fields * Pregnant women * Life expectancy less than 1 year * Inability to receive informed consent * Inability to participate in the entire study * Lack of social security coverage * Refusal to sign consent
💊

What it tests

  • Radiotherapy
  • Observation
  • Vismodegib
📍

Where

1 site
CHU Lille
Lille, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy